G
Guillermo Torre-Amione
Researcher at Baylor College of Medicine
Publications - 121
Citations - 8177
Guillermo Torre-Amione is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Heart failure & Transplantation. The author has an hindex of 41, co-authored 110 publications receiving 7843 citations. Previous affiliations of Guillermo Torre-Amione include Houston Methodist Hospital.
Papers
More filters
Journal ArticleDOI
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
John R. Teerlink,John J.V. McMurray,Robert C. Bourge,John G.F. Cleland,Gadi Cotter,Guillaume Jondeau,Henry Krum,Marco Metra,Christopher M. O'Connor,John D. Parker,Guillermo Torre-Amione,Dirk J. van Veldhuisen,Aline Frey,Maurizio Rainisio,Isaac Kobrin +14 more
TL;DR: The VERITAS program as mentioned in this paper was designed to enroll at least 1760 patients hospitalized with dyspnea at rest because of acute heart failure requiring intravenous therapy, and patients were randomized to receive tezosentan (5 mg/h for 30 minutes, then 1 mg /h for 24-72 hours) or matching placebo.
Journal ArticleDOI
Tumor Necrosis Factor-α: A Mediator of Disease Progression in the Failing Human Heart
Eduardo H. Herrera-Garza,Sonny J. Stetson,Angela Cubillos-Garzon,Mary T. Vooletich,John A. Farmer,Guillermo Torre-Amione +5 more
Journal ArticleDOI
Tumor necrosis factor‐α and the failing human heart–TNFα and heart failure
Hakan Oral,Samir R. Kapadia,Masayuki Nakano,Guillermo Torre-Amione,Joseph Lee,Dorellyn Lee-Jackson,James B. Young,Douglas L. Mann,Douglas L. Mann +8 more
TL;DR: Recent evidence with regard to the biological role for TNFα in the adult mammalian heart is summarized, as well as the increasing body of clinical information that implicates this cytokine in the pathophysiology of heart failure are summarized.
Journal ArticleDOI
Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome.
Guillermo Torre-Amione,Olga Milo-Cotter,Edo Kaluski,Loïc Perchenet,Isaac Kobrin,Aline Frey,Michele M. Rund,Beth Davison Weatherley,Gad Cotter +8 more
TL;DR: The hemodynamic measurements associated with WHF are similar to those predicting adverse outcome in AHF and cardiogenic shock (low cardiac power, higher pulmonary capillary wedge pressure, and vascular resistance), emphasizing the notion that early WHF should become an important AHF-specific outcome measure.
Journal ArticleDOI
Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial.
TL;DR: Preliminary findings are consistent with the hypothesis that immune activation is important in the pathogenesis of HF and establish the basis for a phase III trial to define the benefit of IMT in chronic HF.